Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we've started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhib...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: Frontiers Media SA 2018
Series:Frontiers Research Topics
Subjects:
Online Access:Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication
LEADER 02928namaa2200409uu 4500
001 doab61730
003 oapen
005 20210212
006 m o d
007 cr|mn|---annan
008 210212s2018 xx |||||o ||| 0|eng d
020 |a 978-2-88945-397-9 
020 |a 9782889453979 
024 7 |a 10.3389/978-2-88945-397-9  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
720 1 |a Barbara Melosky  |4 aut 
720 1 |a Vera Hirsh  |4 aut 
245 0 0 |a Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine 
260 |b Frontiers Media SA  |c 2018 
300 |a 1 online resource (95 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers Research Topics 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we've started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine and Nursing  |2 bicssc 
653 |a Metastatic NSCLC 
653 |a Updates on Diagnoses and Treatments 
793 0 |a DOAB Library. 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/61730  |7 0  |z Open Access: DOAB: description of the publication 
856 4 0 |u https://www.frontiersin.org/research-topics/5238/update-on-the-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc-in-new-era-of-personalised-me  |7 0  |z Open Access: DOAB, download the publication